IDARUBICIN, HIGH-DOSE CYTARABINE AND ETOPOSIDE FOR REMISSION INDUCTION IN THERAPY-RELATED ACUTE MYELOID-LEUKEMIA

被引：7

作者：

PHILPOTT, N

MEHTA, J

TRELEAVEN, J

POWLES, R

机构：

[1] Department of Haematology, Leukaemia Unit

[2] The Royal Marsden Hospital, Sutton, Surrey

来源：

LEUKEMIA & LYMPHOMA | 1994年 / 15卷 / 1-2期

关键词：

CYTARABINE; ETOPOSIDE; IDARUBICIN; SECONDARY ACUTE MYELOID LEUKEMIA; THERAPY-RELATED ACUTE MYELOID LEUKEMIA;

D O I：

10.3109/10428199409051686

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Five patients with therapy-related acute myeloid leukemia received combination induction chemotherapy with idarubicin, high-dose cytarabine, and etoposide. Complete remission was achieved in all patients with a single course of therapy. Treatment-related toxicity included nausea, vomiting, mucositis, diarrhea, and liver and kidney function abnormalities, and was low in all patients. There were no deaths during induction therapy. We conclude that this combination is well-tolerated in induction of remission in secondary acute myeloid leukemia, and warrants further assessment because of a very good complete remission rate.

引用

页码：127 / 130

页数：4

共 50 条

[31] A clinical report on high-dose cytarabine therapy for children with acute myeloid leukemia
Wu, Ziliang
Wu, Zelin
Zou, Yawei
Guan, Jingming
Wu, Shangzhi
Chen, Dehui
MOLECULAR AND CLINICAL ONCOLOGY, 2022, 17 (05)
[32] High-dose mercaptopurine and intermediate-dose cytarabine during first remission of acute myeloid leukemia
Canpolat, C
Jeha, S
Lockhart, S
Ramirez, I
Zipf, T
Pinkel, D
CANCER INVESTIGATION, 1997, 15 (02) : 121 - 126
[33] Standard dose of idarubicin and cytarabine is highly effective remission induction therapy for the patients with therapy-related leukemia (TRL): A result of multiinstitutional phase II study.
Yokozawa, T
Takeyama, K
Fukushima, T
Uike, N
Nagata, K
Kagami, Y
Ohno, R
Saito, H
Ueda, R
BLOOD, 1999, 94 (10) : 298A - 298A
[34] A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia
Wang, Amy Y.
Weiner, Howard
Green, Margaret
Chang, Hua
Fulton, Noreen
Larson, Richard A.
Odenike, Olatoyosi
Artz, Andrew S.
Bishop, Michael R.
Godley, Lucy A.
Thirman, Michael J.
Kosuri, Satyajit
Churpek, Jane E.
Curran, Emily
Pettit, Kristen
Stock, Wendy
Liu, Hongtao
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11 : 4
[35] The effect of ffigh dose cytarabine and idarubicin as an induction therapy in biphenotypic acute leukemia
Lee, S
Jung, CW
Song, SY
Park, JO
Kim, K
Kim, WS
Im, YH
Kang, WK
Lee, MH
Park, K
BLOOD, 2002, 100 (11) : 264B - 264B
[36] A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia
Amy Y. Wang
Howard Weiner
Margaret Green
Hua Chang
Noreen Fulton
Richard A. Larson
Olatoyosi Odenike
Andrew S. Artz
Michael R. Bishop
Lucy A. Godley
Michael J. Thirman
Satyajit Kosuri
Jane E. Churpek
Emily Curran
Kristen Pettit
Wendy Stock
Hongtao Liu
Journal of Hematology & Oncology, 11
[37] USE OF HIGH-DOSE CYTARABINE IN AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN ACUTE MYELOID-LEUKEMIA
MOZZANA, R
DELLAVOLPE, A
BUTTI, C
FOSSATI, V
SELVA, S
DELILIERS, GL
LEUKEMIA & LYMPHOMA, 1992, 7 : 45 - 49
[38] HIGH-DOSE ETOPOSIDE MELPHALAN, TOTAL-BODY IRRADIATION AND ABMT FOR ACUTE MYELOID-LEUKEMIA IN 1ST REMISSION
KEATING, A
CRUMP, M
LEUKEMIA, 1992, 6 : 90 - 91
[39] HIGH REMISSION-INDUCTION RATE IN ACUTE MYELOID-LEUKEMIA
GALE, RP
CLINE, MJ
LANCET, 1977, 1 (8010): : 497 - 499
[40] Efficacy and Toxicity of Induction Therapy with Cladribine, Idarubicin, and Cytarabine (IAC) for Acute Myeloid Leukemia
Woelich, Susan K.
Braun, James T.
Schoen, Martin W.
Ramlal, Reshma
Freter, Carl E.
Petruska, Paul J.
Lionberger, Jack M.
ANTICANCER RESEARCH, 2017, 37 (02) : 713 - 717

← 1 2 3 4 5 →